WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that on Tuesday, October 19, 2021, at 8:00 am Eastern Time it will host a Key Opinion Leader (KOL) webinar on istaroxime for the treatment of acute heart failure and the upcoming data in early cardiogenic shock.
The webinar will feature a presentation by KOL John Teerlink, M.D., University of California-San Francisco, who will discuss the current treatment landscape and unmet medical need in treating patients with acute heart failure and the potential role for istaroxime, the company’s product candidate, a first-in-class, dual-action, agent in clinical development for the treatment of acute decompensated heart failure (ADHF).
Windtree’s management team will also discuss the clinical development program for istaroxime, which has been studied in two Phase 2 clinical trials to date. Additionally, Windtree will discuss its development program for istaroxime in early cardiogenic shock, which is currently in a Phase 2 study with targeted completion in Q4 2021.
The Company states that a live Q&A session will follow the formal presentations.
To register for the event, please click here.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.